HK Stock Market Move | HENLIUS (02696) is now up more than 4%. The third phase of clinical research for HLX22 has been completed, with the first patient in the United States being treated.

HENLIUS (02696) has risen by over 4%, with a 4.22% increase to HK$54.35 as of the time of writing, with a trading volume of HK$145.82 million. On the news front, HENLIUS announced that a Phase 3 international multicenter clinical study comparing HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) in combination with trastuzumab and XELOX chemotherapy versus trastuzumab and XELOX with or without pertuzumab for the first-line treatment of HER2-positive locally advanced or metastatic gastroesophageal junction and gastric cancer has successfully dosed the first patient in the United States. This Phase 3 clinical study is also underway in China, Australia, Japan, and other countries and regions. The company stated that HLX22, a novel HER2-targeting monoclonal antibody licensed and developed by the company, has potential indications including gastric cancer and breast cancer. HLX22 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of gastric cancer in March 2025 and May 2025, respectively.